In this episode, Libby speaks with Bill Buschle, Global Director - Coatings, Adhesives, Speciality Chemicals and Elastomers (CASE), at Alchemy Cloud.

Dive into the future of chemical research and development with Libby and Bill. In this insightful podcast, they unravel the challenges faced by R&D teams, emphasising the critical role of process-focused KPIs over binary output metrics. Explore the impact of legacy software and data silos on innovation, and discover how digital integration and AI tools are reshaping the landscape of chemical R&D. The duo share survey insights, shedding light on industry trends and the exciting role of AI in product development. Join the conversation on overcoming challenges in adopting AI and witness the transformation of R&D into a powerhouse of innovation. Stay tuned for success stories and a deep dive into the evolving role of technology in the ever-changing world of chemicals and advanced materials.

To learn more about this topic and the chemicals market at Charlton Morris, drop Libby a message on LinkedIn, here or email at libby.sharpe@charltonmorris.com.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, Emily speaks with Elan Sudberg, CEO of Alkemist Labs and Chair of the American Herbal Products Association's Psychedelic Plants and Fungi Committee.

The committee was chartered in 2022 to address issues related to the safe use and responsible commerce of lawfully marketed products derived from psychedelic plants and fungi. Elan Sudberg was appointed as the committee's first chair. Already CEO of a committed testing laboratory specialising in plant authentication, botanical ingredient identification and quantitative analytical services to the food and beverage, nutraceutical and cosmeceutical industries, he was a perfect fit. His passion for supporting the roll-out of produce with powerful natural benefits to the masses really comes across in this chat, and in the work he is doing across both roles.

He discusses industry trends, recent acquisitions and their impact on the market, and the tricky business of navigating FDA regulations in this fascinating space. There's plenty to glean from this fascinating discussion, with a really interesting window into the future of the nutraceuticals industry.

To learn more about this topic and the wider nutraceuticals market at Charlton Morris, drop Emily a message on LinkedIn, here, or email at emily.austin@charltonmorris.com.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, Indre speaks with Carmen Uphoff, COO of Respeggt, a Dutch-German company aiming to bring positive change to the poultry industry by eliminating chick culling.

During the conversation, Carmen delves into the technology that allows for gender identification in the hatching egg; preventing the culling of undesired male chicks, a practice that results in the death of about 6 billion chicks worldwide each year.

They also touch on the regulatory landscape, noting how Germany and France have already put legislation in place to prevent chick culling, while others are waiting for EU-wide regulations to change, the future of the poultry sector, including the challenges posed by bird flu and the economic crisis. As well as Carmen's insight into a trend leaning towards smaller, more manageable poultry farms as a risk management strategy.

For more insights on animal health and welfare, reach out to Indre on LinkedIn or at indre.semeskeviciute@charltonmorris.com.

Hosted on Acast. See acast.com/privacy for more information.